NantHealth
$2Bpaper valuation
// OVERVIEW
NantHealth spent a decade convincing oncologists that precision medicine required proprietary cloud infrastructure, went public at $2.6 billion in 2016, collapsed to $150 million by 2019, went private again in a take-private deal that valued it at pennies on the original dollar, and now claims to be worth $2 billion again despite generating minimal revenue and operating in a market where AWS, Google Cloud, and Microsoft Azure already won. The $2 billion private valuation exists only in press releases and secondary market whispers — no credible institutional investor has validated it publicly since the take-private.
// HQ
Culver City, United States
// STATUS
PRIVATE
// FOUNDED
2010
// TIER
The Unicorn Herd · $1B – $9.9B
// PRIMARY SECTOR
bioinformatics
// FOUNDERS
// FUNDING ROUNDS
// SECTORS SERVED
// TECHNOLOGY
NantHealth built GPS Cancer, a cloud-based platform that aggregates genomic sequencing data, clinical records, and imaging into treatment decision support tools for oncologists. The core insight was sound in 2011 — precision oncology requires synthesizing massive heterogeneous datasets — but the execution required hospitals to adopt proprietary infrastructure instead of using the cloud platforms they already trusted. The technology works but the distribution model assumed healthcare systems would pay premium prices for a vertically integrated stack when commodity alternatives existed.
// WOWLS ASSESSMENT
NantHealth generated $67 million in revenue in 2018 before going private — roughly what a mid-sized healthcare IT consulting firm earns without claiming to revolutionize oncology. The company burned through hundreds of millions proving that precision medicine is a data problem but not necessarily a proprietary platform problem. Tempus raised $1.3 billion and built genomic sequencing infrastructure by integrating with existing hospital EMRs rather than replacing them. Foundation Medicine was acquired by Roche for $2.4 billion using the same integrate-don't-replace strategy. NantHealth's competitive position deteriorated so severely between 2016 and 2019 that founder Patrick Soon-Shiong took it private at a 94% discount to peak valuation rather than continuing to report quarterly losses to public shareholders. The $2 billion resurrection valuation has no documented institutional backing.
// WHY WOWLS HUNTS THIS
The $2 billion private valuation represents either spectacular institutional gullibility or founder self-dealing — and either explanation makes this a target. NantHealth is what happens when a billionaire's ego meets a failed public company and decides the problem was transparency, not the business model.
// VALUATION NOTE
The $2B private valuation appears nowhere in credible institutional filings. NantHealth went public in 2016 at $2.6B, collapsed to market cap below $200M by 2019, and was taken private by founder Patrick Soon-Shiong. The claimed $2B resurrection has no documented third-party validation and likely represents internal valuation for accounting purposes rather than genuine market pricing.
VERDICT: ZOMBIECORN — A $2.6 BILLION PUBLIC MARKET COLLAPSE FOLLOWED BY A TAKE-PRIVATE AT 94% DISCOUNT DOES NOT BECOME A $2 BILLION SUCCESS STORY JUST BECAUSE THE FOUNDER CONTROLS THE VALUATION PROCESS AGAIN
// PACK DEBATE
// PACK DEBATE — be the first to weigh in
Google account required — no spam, no nonsense
// LOADING INTEL…
// BROADCAST INTEL
// SIMILAR TARGETS
// INTEL UPDATED: MAY 2026
// INTELLIGENCE DISCLAIMER: Assessments represent editorial opinion based on publicly available data including filings, press reports, and market data as of the date shown. Valuations are approximate. Not financial or investment advice.
// FULL NETWORK ACCESS
🚀 Founder Briefing: Instantly sort investors by Sector, Stage, & Round — direct links to websites for all 1,030 unicorns & backing VCs included.
Don't just track NantHealth.
Master the entire 1,030 unicorn company intelligence network.
Stop analyzing tech monopolies one page at a time. Instantly filter, sort, and isolate the exact venture capital firms, angel investors, and corporate funds backing your specific market vertical. Find investors that fit your sector and deploy your pitch with direct outbound links to every target asset in the database — 1,030 targets total.
Acquire Intel →// 5 TIERS · PAYPAL SECURED
// ENGAGE THE FULL ARSENAL
Done reading on NantHealth?
Unlock the entire 1,030-company hitlist and 1,030 investor contacts.
Full structural breakdowns. Founder dossiers. VC outreach data. Threat-level intel updated continuously.
→ Deploy 5-Tier Order Form// ARBAN · ZUUN · MINGHAN · TUMEN · KHAN